Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lippens

Showing results (461-470 of 477) with videos related to

Pageof 48
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2018
MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotypeEmilie Plantamura, Amiran Dzutsev, Mathias Chamaillard, et al.
Neurobiology of Aging|August 29, 2012
Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarkerKunie Ando, Pierre Dourlen, Anne-Véronique Sambo, et al.
Gynecologic Oncology|November 8, 2024
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trialEmiel A De Jaeghere, Hannelore Hamerlinck, Sandra Tuyaerts, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2024
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO studyEmiel A De Jaeghere, Sandra Tuyaerts, An M T Van Nufel, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2022
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO studyEmiel A De Jaeghere, Sandra Tuyaerts, An M T Van Nuffel, et al.
Analytical Chemistry|June 23, 2026
NMR of Fully and Partially <sup>13</sup>C-Enriched Biomass Enhances Pendent Group Structural CharacterizationJohn Ralph, Guy Lippens, Marco Tonelli, et al.
Nature Communications|September 24, 2015
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in miceRebecca Deprez-Poulain, Nathalie Hennuyer, Damien Bosc, et al.
Biomarker Research|April 14, 2025
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemiaArnaud Métois, Marie-Eve Bordeleau, Louis Theret, et al.
Nature|December 27, 2016
The role of fatty acid β-oxidation in lymphangiogenesisBrian W Wong, Xingwu Wang, Annalisa Zecchin, et al.
Nature Communications|July 25, 2019
The generation and use of recombinant extracellular vesicles as biological reference materialEdward Geeurickx, Joeri Tulkens, Bert Dhondt, et al.
Pageof 48

Showing results (461-470 of 477) with videos related to

Sort By:
Pageof 48
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2018
MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotypeEmilie Plantamura, Amiran Dzutsev, Mathias Chamaillard, et al.
Neurobiology of Aging|August 29, 2012
Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarkerKunie Ando, Pierre Dourlen, Anne-Véronique Sambo, et al.
Gynecologic Oncology|November 8, 2024
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trialEmiel A De Jaeghere, Hannelore Hamerlinck, Sandra Tuyaerts, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2024
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO studyEmiel A De Jaeghere, Sandra Tuyaerts, An M T Van Nufel, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2022
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO studyEmiel A De Jaeghere, Sandra Tuyaerts, An M T Van Nuffel, et al.
Analytical Chemistry|June 23, 2026
NMR of Fully and Partially <sup>13</sup>C-Enriched Biomass Enhances Pendent Group Structural CharacterizationJohn Ralph, Guy Lippens, Marco Tonelli, et al.
Nature Communications|September 24, 2015
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in miceRebecca Deprez-Poulain, Nathalie Hennuyer, Damien Bosc, et al.
Biomarker Research|April 14, 2025
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemiaArnaud Métois, Marie-Eve Bordeleau, Louis Theret, et al.
Nature|December 27, 2016
The role of fatty acid β-oxidation in lymphangiogenesisBrian W Wong, Xingwu Wang, Annalisa Zecchin, et al.
Nature Communications|July 25, 2019
The generation and use of recombinant extracellular vesicles as biological reference materialEdward Geeurickx, Joeri Tulkens, Bert Dhondt, et al.
Pageof 48